Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xention Siphons Off OAB Therapy Into New Spin Out, Provesica

This article was originally published in The Pink Sheet Daily

Executive Summary

Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica

You may also be interested in...

U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy

New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.

Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation

First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.

PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy

The $170 million up-front that Abbott Laboratories ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down-payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts